Tests KIVU-107 in adults with advanced solid tumors
Tests KIVU-107, a targeted drug, for safety in adults with advanced solid tumors.
Plain-language title generated from the registry record
Registry title: A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Key facts
- Where
- New Have and Santa Monica, United StatesSee the 2 sites
- Phase
- Phase 1
Where in United States
- New HaveNew Have, United StatesTaking people
- Santa MonicaSanta Monica, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Kivu Bioscience Inc.
- Trial code
- NCT07229313
- Record updated
- 24 September 2026
- Original description
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.Read full original descriptionShow less
A Phase 1 Dose-Finding and Dose-Expansion Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
Inclusion: Male or female ≥18 years of age; No therapy of proven efficacy exists for the tumor; Pathologically or histologically documented diagnosis of advanced / metastatic solid tumor malignancy that is resistant to standard therapy or for which no standard therapy is available; Adequate bone marrow, kidney, and liver function; Measurable disease using RECIST v1.1; ECOG 0 or 1; Life expectancy ≥ 3 months.
Exclusion: Prior treatment with any ADC with topoisomerase 1 inhibitor payload; Any PTK7 - targeted therapy; Uncontrolled cardiovascular disease; Active Hepatitis B, Hepatitis C, or HIV infection; History of interstitial lung disease; Major surgery, radiation therapy, or systemic anti-cancer within 3 weeks of study treatment start.